A Huntington disease genetic test counts a repeated DNA sequence called CAG in the HTT gene. The result can confirm Huntington disease in someone with symptoms, show whether an adult at family risk inherited an expanded repeat before symptoms begin, or help with reproductive planning. Unlike many genetic tests, this test usually does not search for a spelling change across a large gene. It directly measures repeat length, and the reported number is placed into a range with a defined clinical meaning. A result of 40 or more CAG repeats is expected to cause Huntington disease during a typical lifetime, while 36 to 39 repeats have reduced penetrance and may or may not lead to symptoms. Testing can bring clarity, but it cannot predict the exact age symptoms will start, their order, or how quickly they will progress. Because a predictive result may affect emotional health, relationships, insurance decisions, and relatives, testing should be arranged through an experienced genetics or Huntington disease team.
- The test measures the CAG repeat length in both copies of HTT.
- Results are classified as normal, intermediate, reduced penetrance, or full penetrance.
- A positive predictive result does not mean symptoms are already present.
- The repeat count cannot forecast an exact age of onset or disease course.
- Each child of a person with an expanded HTT allele usually has a 50% chance of inheriting it.
- Pretest counseling is a central part of testing an adult who has no clear symptoms.
Table of Contents
- What the Huntington disease test measures
- Diagnostic, predictive, and reproductive testing
- CAG repeat result ranges
- What repeat length can and cannot predict
- How predictive testing is done
- Inheritance, anticipation, and family risk
- Technical limitations and unexpected results
- Next steps after results
What the Huntington disease test measures
Huntington disease is caused by an expanded CAG trinucleotide repeat in HTT. CAG is a three-letter DNA sequence. Everyone has a stretch of CAG repeats in each of their two HTT copies, one inherited from each biological parent. The laboratory reports the repeat count for both alleles, such as 18 and 42. In that example, 18 is in the normal range and 42 is a disease-causing expansion.
The test is a targeted repeat analysis. A laboratory commonly uses polymerase chain reaction, or PCR, to copy the repeat region and estimate its size. Additional techniques may be needed when an expansion is very large or when the initial pattern looks as though both alleles have the same normal repeat count. Triplet-primed PCR can reveal the presence of a large expansion that ordinary PCR may fail to size accurately. Some laboratories use other expansion-analysis methods when needed.
This focused approach differs from routine gene sequencing. Standard sequencing is designed to find substitutions and small insertions or deletions, but it may not reliably measure a long repetitive tract. A broad neurologic genetic panel or exome test can miss an HTT expansion unless the laboratory has added a validated repeat-detection method. When Huntington disease is the specific concern, the order should clearly request HTT CAG repeat analysis.
The test answers whether an expanded repeat is present. It does not, by itself, establish whether a person currently has clinical Huntington disease. Diagnosis still combines the molecular result with a neurologic and behavioral assessment. A person can carry a disease-causing expansion for years before recognizable symptoms appear. Conversely, someone can have chorea, personality change, or cognitive decline for another reason and have two HTT alleles outside the disease-causing range.
Diagnostic, predictive, and reproductive testing
The purpose of testing determines how the result should be handled. Diagnostic testing is used when a person has findings that may represent Huntington disease. These can include involuntary movements, loss of coordination, slowed voluntary movement, changes in judgment or planning, depression, irritability, apathy, or other behavioral changes. A clinician first reviews the pattern, timing, medication history, examination, and family history. HTT testing can then confirm or exclude the usual molecular cause of Huntington disease.
Predictive, also called presymptomatic, testing is different. It is offered to an adult who has no definite signs of Huntington disease but is at risk because a biological parent or another close relative has the condition. The result may show that the person inherited the familial expansion, yet it cannot say when symptoms will begin. A structured presymptomatic genetic testing process helps the person decide whether knowing now is likely to be useful and emotionally manageable.
Testing may also be requested when a family diagnosis is uncertain. Whenever possible, the best first step is to confirm the HTT expansion in a relative who clearly has symptoms. That establishes that Huntington disease is truly the condition in the family. Testing an unaffected relative without first confirming the family diagnosis can produce confusion, particularly if the family history was based only on a label such as “chorea,” “dementia,” or “psychiatric illness.”
Reproductive uses include prenatal diagnosis during pregnancy and preimplantation genetic testing with in vitro fertilization. Some approaches can determine whether an embryo or fetus inherited the expanded allele. Exclusion testing may sometimes be designed so that a person at 50% risk can reduce the chance of passing on the family chromosome without learning their own status. These choices involve medical, emotional, financial, and ethical considerations and should be discussed before pregnancy whenever possible.
Testing children who have no symptoms is generally not recommended for an adult-onset condition because there is no childhood medical action that depends on the result, and the child should usually retain the future right to decide. Testing a minor may be appropriate when a clinician suspects juvenile-onset Huntington disease based on significant neurologic or developmental findings. That is diagnostic evaluation, not routine predictive testing.
CAG repeat result ranges
The laboratory classifies the larger of the two HTT repeat counts. The ranges below describe the standard interpretation, but a genetics professional should review the exact report, assay, and family context.
| CAG repeat count | Usual classification | Meaning for the tested person | Meaning for children |
|---|---|---|---|
| 26 or fewer | Normal allele | Not expected to cause Huntington disease | Generally stable and not expected to expand into the disease range in one generation |
| 27–35 | Intermediate allele | Usually not expected to cause classic Huntington disease | Can be unstable, especially during paternal transmission, and may expand in a child |
| 36–39 | Disease-causing allele with reduced penetrance | Huntington disease may develop, but some people remain unaffected through a normal lifespan | Each child has a 50% chance to inherit the allele; repeat size can change |
| 40 or more | Full-penetrance disease-causing allele | Expected to cause Huntington disease during a typical lifespan, although timing varies | Each child has a 50% chance to inherit the allele; repeat size can change |
A normal result means both alleles are 26 repeats or fewer. In a person with convincing symptoms, this makes classic HTT expansion–related Huntington disease very unlikely. It does not explain the symptoms, so the clinician may investigate medications, autoimmune or metabolic disorders, acquired brain disease, or genetic conditions that resemble Huntington disease.
An intermediate allele is not usually considered a predictive positive result for the tested person. Most people with 27 to 35 repeats do not develop classic Huntington disease. Its main importance is reproductive: the repeat can be unstable when passed to the next generation. Risk is not identical across this entire range. Larger intermediate alleles, particularly when transmitted by a father, have a greater chance of expanding.
A reduced-penetrance result of 36 to 39 repeats is genuinely disease-causing but uncertain at the individual level. Some carriers develop typical Huntington disease, often later in life, and others never develop recognizable symptoms. It is incorrect to translate this result into a guaranteed diagnosis or a simple percentage without considering age, ancestry, family history, repeat structure, and the limits of available estimates.
A result of 40 or more repeats is called full penetrance because people who live a usual lifespan are expected to develop the disorder. The result still does not show that symptoms have started today. Clinical status is determined separately. Very long expansions are more often associated with childhood or adolescent onset, but repeat length alone should not be used to diagnose juvenile Huntington disease without an appropriate evaluation.
What repeat length can and cannot predict
Across large groups, longer uninterrupted CAG stretches are associated with earlier average onset. This is a population relationship, not a personal calendar. Two people with the same reported repeat count can begin having symptoms many years apart. Other genetic modifiers, changes in repeat length within body tissues over time, general health, environment, and chance all contribute.
A report therefore cannot reliably state, “Symptoms will begin at age 43.” Online calculators and research models may estimate an age distribution for groups, but the uncertainty can be wide, especially for smaller expansions. Such estimates should not be used as fixed deadlines for work, relationships, parenting, or financial decisions.
Repeat number also does not predict which feature will appear first. One person may first have subtle coordination or eye-movement changes. Another may show apathy, depression, irritability, reduced flexibility in thinking, or problems organizing tasks before obvious chorea. Behavioral symptoms can have many causes and should not automatically be labeled Huntington disease in a carrier. A careful clinical assessment remains important because common, treatable conditions can occur independently.
The count is also an imperfect guide to progression. Larger expansions are associated with some group-level differences, but they do not determine the exact rate of decline, degree of chorea, psychiatric burden, response to treatment, or life expectancy for one person. A molecular result establishes inherited risk; longitudinal clinical care describes the individual course.
The wording “positive” can be misleading in predictive testing. It means an expanded allele was found, not that a neurologic examination is positive and not that disability is imminent. Similarly, “negative” means the familial HTT expansion was not inherited, but it does not guarantee lifelong freedom from unrelated movement, cognitive, or psychiatric conditions. The result should be stated in precise terms: repeat counts, classification, and whether the person currently has symptoms.
Research increasingly distinguishes the total length reported by standard assays from the length of the uninterrupted CAG tract. Interrupting sequences can modify stability and onset. These findings improve biological understanding, but many routine clinical reports still use the conventional repeat count and ranges. A specialist can determine whether additional characterization is appropriate near a boundary or when the phenotype and result do not fit.
How predictive testing is done
Predictive testing is a process rather than a single blood draw. Established programs commonly involve a genetic counselor, neurologist or other clinician familiar with Huntington disease, and access to mental health support. The aim is not to make a person prove that they can cope. It is to support an informed, voluntary decision and prepare for either result.
The first visit reviews the family diagnosis and constructs a detailed pedigree. The team explains the 50% inheritance risk, result ranges, limits of age prediction, privacy considerations, and possible effects on relatives. They ask what the person hopes the test will change. Reasons may include ending uncertainty, planning children, organizing finances, explaining subtle concerns, or deciding whether to join research. Choosing not to test is equally valid.
A mental health assessment looks for current depression, severe anxiety, substance misuse, suicidal thinking, coercion, or an unstable life crisis. These issues do not automatically prohibit testing, but stabilizing them first can reduce harm. The team helps identify a support person and makes a plan for the day results are given and the weeks afterward. Results are preferably delivered in person or through a secure clinical visit, not released without context through an electronic portal.
The person should consider practical consequences before the sample is collected. Rules governing health, life, disability, employment, and long-term-care insurance differ by country and policy type. A genetics professional or qualified local adviser can explain applicable protections without making assumptions. People may also want to decide what will be documented in the medical record and how they will communicate with family members.
Some protocols schedule several visits and a reflection period; others tailor the pace to the person. The core safeguards are informed consent, voluntariness, accurate education, psychological readiness, and planned follow-up. A competent adult may stop the process at any point, including after giving a sample but before learning the result, subject to laboratory and clinic procedures.
Predictive testing should not be ordered secretly by a relative, partner, employer, insurer, or clinician. Testing one family member can indirectly reveal information about others, but each person retains autonomy over their own testing. When family pressure is strong, private counseling can clarify whose decision is being made.
Inheritance, anticipation, and family risk
Huntington disease follows an autosomal dominant inheritance pattern. A person with one expanded HTT allele usually has one non-expanded allele as well. For each pregnancy, there is a 50% chance the expanded allele will be passed on and a 50% chance the non-expanded allele will be passed on. The probability resets with every pregnancy; prior children do not alter the next child’s chance. An autosomal dominant genetic test result can therefore have immediate relevance for siblings, adult children, and future pregnancies.
A person who did not inherit the familial expansion cannot pass that expansion to children. A person with an intermediate allele presents a different situation: the tested person will usually not develop classic Huntington disease, but the repeat may expand during formation of eggs or sperm. Counseling should address the actual repeat size and the sex of the transmitting parent rather than treating every intermediate result alike.
Anticipation describes earlier onset or more severe disease in a later generation because the repeat becomes longer. CAG repeats can expand or contract through either parent, but large expansions occur much more often during paternal transmission. Many cases of juvenile-onset Huntington disease result from a substantial expansion inherited from the father. Anticipation is a family-level pattern, not a certainty for each child.
A newly diagnosed person may appear to have no family history. An affected parent may have died before onset, been misdiagnosed, had very late or mild disease, carried a reduced-penetrance allele, or not been biologically related as assumed. An intermediate allele can also expand into a disease-causing range in a new generation. Therefore, absence of a known family history does not exclude Huntington disease.
Sharing results with relatives can be difficult. The clinical team can provide a family letter that explains the finding without exposing unrelated medical details. Relatives should not be told that they “have Huntington disease” solely because a family member tested positive. Their risk depends on their relationship and may be clarified only by their own counseling and testing.
Family-building options include natural conception with or without prenatal diagnosis, in vitro fertilization with preimplantation genetic testing, use of donor eggs or sperm, adoption, or deciding not to have children. None is universally correct. A reproductive genetics team can explain success rates, timing, costs, test design, and whether the familial expansion must first be confirmed in a particular relative.
Technical limitations and unexpected results
HTT repeat testing is highly accurate when performed by an experienced laboratory, but no assay is free of limitations. Ordinary PCR can preferentially amplify the smaller allele. If a person appears to have two identical normal alleles, a very large expansion could theoretically be hidden. Laboratories address this risk with triplet-primed PCR or another method designed to detect large repeats, particularly when the clinical suspicion is strong.
Measurement has a laboratory-specific uncertainty, especially for long repeats. Reports may include an estimated size or a precision range. A one-repeat difference near 35/36 or 39/40 can change the formal category, so borderline results deserve careful review. The clinician should confirm that the laboratory follows current technical standards and reports both allele sizes and the method used.
Most HTT alleles contain interruptions near the CAG tract. Rare loss-of-interruption variants can make the uninterrupted CAG run longer than the conventional assay suggests. In some people reported with 34 or 35 repeats, the biologically relevant uninterrupted tract may fall into a disease-associated range. Such variants can also modify onset among people with 36 to 39 repeats. Additional sequence analysis may be considered when a person has convincing Huntington-like symptoms but a boundary-range result, or when a specialist believes the repeat structure would materially change counseling.
A negative HTT expansion result in a symptomatic person is not the end of the evaluation. Huntington disease–like presentations can result from other inherited disorders, including certain repeat expansions, dominant neurodegenerative conditions, metabolic diseases, and mitochondrial disorders. Acquired causes include medications, autoimmune disease, infection, stroke, and other structural brain conditions. The next test should be guided by age, ancestry, examination, imaging, psychiatric features, and family pattern rather than automatically ordering the largest available panel.
Occasionally, the test reveals a result the family did not expect, such as an intermediate allele in a person thought to be at no risk, a reduced-penetrance allele in an older unaffected adult, or two expanded alleles. The report may also expose an inconsistency in assumed biological relationships. These findings need confidential, nonjudgmental counseling. A variant result explanation designed for sequence variants is not a substitute for repeat-specific interpretation because HTT categories are based primarily on repeat size and penetrance.
Direct-to-consumer raw data and research reports should not be used for life-changing decisions without confirmation in a clinical laboratory. Many consumer genotyping arrays do not directly measure HTT CAG repeat length. An inferred risk marker near HTT is not the same as detecting the expansion.
Next steps after results
After a diagnostic positive result, the person should be referred to a multidisciplinary Huntington disease clinic when available. Care may involve neurology, psychiatry, psychology, genetics, physical therapy, occupational therapy, speech-language pathology, nutrition, social work, and primary care. Treatment is tailored to current symptoms. Medications can reduce chorea or address depression, anxiety, irritability, psychosis, sleep disturbance, and other concerns, but each drug’s benefits and adverse effects must be weighed individually.
Baseline assessment documents movement, cognition, mood, function, swallowing, weight, driving, work safety, and support needs. Follow-up focuses on meaningful change rather than repeatedly rechecking the CAG repeat, which generally does not need to be measured again. Planning can include advance directives, financial and legal arrangements, workplace accommodations, fall prevention, communication strategies, and caregiver support. These discussions should be paced according to the person’s priorities rather than delivered as a single overwhelming list.
After a predictive expansion result in someone without definite symptoms, immediate treatment may not be needed. A specialist can establish a baseline and agree on a follow-up schedule. Some people prefer regular visits; others want less frequent contact unless concerns arise. Healthy sleep, physical activity, management of cardiovascular risks, treatment of mood disorders, and avoidance of harmful substance use support general health, although they are not proven to prevent Huntington disease.
A negative predictive result often brings relief but can also bring survivor guilt, a changed identity, or tension with relatives who remain at risk. Follow-up counseling remains appropriate. The person no longer needs Huntington-specific surveillance due to the familial expansion and cannot pass that expansion to children, assuming the family mutation was correctly established and the test was technically complete.
Intermediate and reduced-penetrance results merit a dedicated genetics visit rather than a brief “uncertain” label. The discussion should cover what is known for that exact repeat count, the limits of penetrance estimates, reproductive risk, whether interruption testing is relevant, and what symptoms should prompt evaluation. Repeating the same standard test usually does not resolve biological uncertainty.
Research participation may offer access to observational studies or clinical trials, but it is not a substitute for clinical care and does not guarantee personal benefit. Eligibility depends on age, repeat length, symptoms, stage, and study design. The team should distinguish validated clinical tests from research biomarkers such as imaging measures, neurofilament light, or measures of somatic repeat expansion.
Any new severe depression, suicidal thoughts, psychosis, dangerous impulsivity, rapidly worsening swallowing, repeated falls, or inability to remain safe requires urgent medical assessment. Huntington disease can affect the whole family, so support should extend to partners, children, caregivers, and relatives making their own testing decisions. The most useful result is one delivered with a clear interpretation, an individualized care plan, and continued access to help.
References
- Huntington Disease (2026, GeneReviews)
- Improving the Clinical Diagnostic Criteria for Genetically Confirmed Huntington Disease (2025)
- Sequence Variants in Small CAG Repeat Expansions of the HTT Gene and Disease Onset and Progression in Huntington Disease (2026)
- Huntington Disease Update: New Insights Into the Role of Repeat Instability in Disease Pathogenesis (2022)
- Advances in Huntington’s Disease Biomarkers: A 10-Year Bibliometric Analysis and a Comprehensive Review (2025)
- American College of Medical Genetics and Genomics Technical Standards and Guidelines for Huntington Disease (2021)
Disclaimer
This article is for general education and does not replace evaluation, genetic counseling, diagnosis, or treatment from qualified health professionals. Huntington disease testing has important medical, psychological, reproductive, privacy, and family implications, so results should be interpreted by an experienced clinical team. Seek urgent local medical help for suicidal thoughts, dangerous behavior, severe psychiatric symptoms, or an immediate safety concern.
